Dysregulated Expression of Soluble Immune Mediator Receptors in a Subset of Patients with Chronic Fatigue Syndrome:

References

• Holmes GP, Kaplan JE, Gantx NM et al. Chronic fatigue syndrome: a working case definition. Ann. Intern. Med. 1988;108:387–389.
   PubMed Web of Science ®Google Scholar
• Patuca R, Fletcher MA, Klimas NG. Immunological correlates of chronic fatigue syndrome. In: P. Goodnick and N.G. Klimas, eds. Chronic fatigue and related immune deficiency syndromes. American Psychiatric Press, Inc., Washing-ton, D.C. 1993:1–21.
   Google Scholar
• Buchwald D, Cheney PR, Peterson DL, Henry B et al.: Chronic illness characterized by fatigue, neurologic and immunologic disorders and active human herpesvirus type 6 infection. Ann Int Med. 1992;116:103–113.
   PubMed Web of Science ®Google Scholar
• Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormal-ities in chronic fatigue syndrome. J. Clin. Microbiol. 1990;28:1403–1410.
   PubMed Web of Science ®Google Scholar
• Landay AL, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991;338:707–712.
   PubMed Web of Science ®Google Scholar
• Patorca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA. Dysregu-lated expression of tumor necrosis factor in chronic fatigue syndrome: Interrela-tions with cellular sources and patterns of soluble immune mediator expression. Clin. Infect. Dis. 1994;18:S147–S153.
   Google Scholar
• Linde A, Andersson B, Svenson SB et al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J. Inf. Dis. 1992;165:994–1000.
   PubMed Web of Science ®Google Scholar
• Caliguri hi, Murray C, Buchwald D, Levine H, Cheney P. Peterson D, Komaroff AL, Ritsz J. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J. Immunol. 1987;139:3306–3313.
   Google Scholar
• Ojo-Amaise EA, Conley EJ, Peters JB. Decreased natural killer cell activ-ity is associated with severity of chronic fatigue immune deficiency syndrome. Clin Inf Dis 1994;18:S157–S159.
   Google Scholar
• Lloyd AR, Wakefield D, Boughton CR et al. Immunological abnormalities in the chronic fatigue syndrome. Med. J. Aust. 1989;151:122–124.
   PubMed Web of Science ®Google Scholar
• Komaroff AL, Geiger AM, Wonnsley S. IgG subclass deficiencies in chronic fatigue syndrome. Lancet. 198.8;1:1288-1289.
   Google Scholar
• Read R, Spickett G, Harvey J et at. IgG1 subclass deficiency in patients with chronic fatigue syndrome (letter). Lancet 1988;1:241–242.
   Google Scholar
• Fletcher MA, Azen SP, Adelsberg B et al. Immunophenotyping in a multi-center study: the transfusion safety study experience. Clin. Immunol. Immunopa-thol. 198952: 38–47.
   Google Scholar
• Parker I, Adelsberg B, Boone D, Fletcher MA, Gjerset G, Kaplan J, Niland J, Odom-Maryon T, Operskalski E, Prince H, Scott D, Stites D, Mosley J and the Transfusion Safety Study Group. Leukocyte Inununophenotyping by Flow Cyto-metry in a Multisite Study: Standardization, Quality Control and Normal Values in the Transfusion Safety Study Clin. Immunol. Inununopath. 1990;55:187–220.
   Google Scholar
• Fletcher MA, Klimas NG, Morgan R, Gjerset G. Lymphocyte Proliferation Assays. In: Rose N and Fahey J, eds., J. Manual of Clinical Laboratory Immunol-ogy, 4th edition., Amer. Soc. Microbiology, 1992:213–219.
   Google Scholar
• Baron GA, Klimas NG, Fischl MA and Fletcher MA. Decreased Natural Killer Cell-Mediated Cytotoxicity Per Effector Cell. Diag. Inununol. 1985;3:197–204.
   Google Scholar
• Fletcher MA, Baron GC, Ashman MR, Fischl MA, Klimas NG. The use of whole blood methods in assessment of immune parameters in immunodeficiency states. Diagn. Clin. Immunol. 1987;5:69–81.
   Google Scholar
• Cope AP, Aderka D, Doherty M et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992;35:11601169.
   Google Scholar
• Chikanza IC, Roux-Lombard P, Dayer J-M, Panayi GS. Tumor necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin. Exp. Immunol. 1993;92:19–22.
   PubMed Web of Science ®Google Scholar
• Gallati H, Brockhaus M. Detection of soluble TNF receptors in biological fluids. Eur. Cytokine Netw. 19923: 264.
   Google Scholar
• Heilig B, Fiehn C, Brockhaus M, Gallati H, Pezzutto A, Hunstein W. Eval-uation of soluble tumor necrosis factor (TNF) receptors and TNF receptor anti-bodies in patients with systemic lupus erythematodes, progressive systemic scle-rosis, and mixed connective tissue disease. J. Clin. Immunol. 1993;13:321–328.
   PubMed Web of Science ®Google Scholar
• Taga T, Kishimoto T. Role of a two-chain IL-6 receptor system in immune and hernatopoietic cell regulation. Crit. Rev. Immunol. 1992;11:265–280.
   PubMed Web of Science ®Google Scholar
• Gatanaga T, Lentz R, Masunaka I, Tornich J III, Jeffes EWB, Baird M, Granger GA. Identification of TNF-LT blocking factor(s) in the serum and ultra-filtrates of human cancer patients. Lyrnphokine Res. 1990;9:22.5–229.
   Google Scholar
• Aderka D, Engelmann H, Hornik V et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991;51:5602–5607.
   PubMed Web of Science ®Google Scholar
• Gaillard IF, Bataille R, Brailly H et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gam-mopathy. Eur. J. Immunol. 1993;23:820–824.
   PubMed Web of Science ®Google Scholar
• Kalinkovich A, Livshits G, Engelmann H et al. Soluble tumor necrosis fac-tor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytes. Clin. Exp. Immunol. 1993;93:350–355.
   PubMed Web of Science ®Google Scholar
• Godfried MK Van der Poll T, Jansen J et al. Soluble receptors for tumour necrosis factor a putative marker of disease progression in HIV infection. AIDS 1993;7:33–36.
   PubMed Web of Science ®Google Scholar
• Honda M, Yamamoto S, Chang M et al_ Human soluble IL-6 receptor. Its detection and enhanced release by HIV infection. J. Immunol. 1992148: 2175–2180.
   Google Scholar
• Cadranel J, Philippe C, Philippe B, Milleron B, Fouqueray B, Mayaud C, Baud L Increased expression and occupancy of receptors for tumour necrosis fac-tor on blood monocytes from tuberculosis patients. Clin. Exp. Immunol. 1993;94:51–56.
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Williiam D, El-Sadr W, Marmor M, Stahl R. Quantitation of p2-microglobulin and other immune characteristics in a progressive study of men at risk for acquired irrununodeficiency syndrome. JAMA 1984;22: 2951–2955.
   Google Scholar
• Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GHW, Gatanaga T, Granger GA, Lentz R, Raab H, Kohr WJ, Goeddel DV. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 1992;61:361–370.
   Web of Science ®Google Scholar
• EngelmannAderka M, Rubinstein M, Rotman M, Rotman D, WallachD. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 1989;264: 11974–11980.
   Google Scholar
• Seckinger P. 1ssaz S, and Dayer J-M. Purification and biologic character-ization of a specific tumor necrosis factor a inhibitor. I. Biol. Chem. 1989;264:11966–11973,
   Google Scholar
• Foxwell BMJ, Barrett K, Feldmann M. Cytokine receptors: structure and signal transduction. Clin. Exp. Immunol. 1992;90:161–169.
   Google Scholar
• Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol. Today 1992;13: 151–153.
   PubMedGoogle Scholar
• Yasulcawa K, Saito T, Fukunaga T et al. Purification and characterization of soluble human 1L-6 receptor expressed in CHO cells. J. Biochem. 1990;108:673–676.
   PubMed Web of Science ®Google Scholar
• Saito T, Yasukawa K, Suzuki H et al. Preparation of soluble murine 1L-6 receptor and anti-murine 1L-6 receptor antibodies. J. Inununol. 1991;47:168–173.
   Google Scholar
• Tamura T, Udagawa N, Takahashi N et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc. Natl. Acad. Sci. USA 1993; 90:11924–11929.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 199177:1627-1652.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Gelfand IA, Wolff SM. Anticytokine strategies in the treat-ment of the systemic inflammatory response syndrome. JAMA 1993;269:1829–1835.
   Google Scholar
• Keller RH, Lane IL, Klimas N, Fletcher MA, van Riel F, Morgan R. Association between HLA class 11 antigens and the chronic fatigue immune dys-function syndrome. Clin. Inf. Dis. 1994;18:S154–S156.
   PubMed Web of Science ®Google Scholar
• Jacob CO, Zdenka F, Lewis GD, Koo M, Hansen JA, McDevitt HO. Herit-able major histocompatibility complex class 11-associated differences in produc-tion of tumor necrosis factor a: Relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 1990;87: 1233–1238.
   PubMed Web of Science ®Google Scholar